On 7 July, the PERMIT consortium met for its third General Assembly, to go over the achievements conducted over the past 6 months, and to discuss the activities for the next semester. In total nine different working sessions, focus groups and stakeholder consultations were held between February and July within work packages 3 to 6.
On 12 July, the PERMIT project held an online working session to discuss the regulatory gaps in the personalised medicine research pipeline. Gathering over 30 participants from within and beyond the PERMIT consortium, the session focused on the gaps and questions identified through the scoping reviews and consultation exercises.
In July, PERMIT WP6 hosted two working sessions mainly focused on three specific trial designs commonly used in the field of personalised medicine (platform, umbrella and basket design). Experts in the field discussed how these three complex trial designs can be used for the development of personalised medicine, their advantages, and their disadvantages.
PERMIT WP3 hosted two workshops to delve into tools and methods for designing, planning, and conduct stratification and validation cohorts.
The PERMIT project is featured in the latest video from the ICPerMed family video series.
Cellular models for personalised medicine were the last topic in the series of virtual working sessions focused on preclinical methods for personalised medicine, hosted on June 30th by WP5.
PERMIT WP5 hosted its third virtual working session, with focus on animal models for personalised medicine, on June 22nd.
Machine learning and bioinformatics experts from different European countries and representatives from the PERMIT consortium met for an online workshop on 18 June 2021, to discuss the current challenges and limitations in machine learning (ML) analyses of omics data for patient stratification.
Shortly after the successful focus group to explore the industry perspective on preclinical research, the second working session on June 1st assessing the translational development phase looked at in silico models for personalised medicine. During this second meeting, the group, composed of five experts from the field, explored some common bottlenecks and potential solutions. The importance of high-quality data collection and sharing was debated, as well as the relevance of model validation for ensuring reliable results and regulation-related issues.
On May 26th 2021, the first working session organised in the context of PERMIT’s WP5, translational development of patient-stratification processes, was held as a virtual meeting. It analysed the pharmaceutical industry perspective on preclinical research for personalised medicine.
No generic approach for sample size estimation can be made in personalised medicine when designing a stratification cohort. The conclusion is drawn from the first stakeholder consultation by the PERMIT project which looked to identify approaches to estimate the number of patients needed to be included in a cohort for different types of stratification studies using machine learning.
The PERMIT Project held its second General Assembly meeting on the 15th of January 2021. All consortium members gathered to share the milestones and achievements of the first year, focusing on the outcomes of the scoping review of PM methodologies. During the meeting, the work plan for 2021 was also presented and discussed.
On December 1 and 2, 2020 the PERMIT project held its Gap Analysis Workshop. This important milestone of the project corresponds to the final phase of the scoping review process that was carried out in the first year of the project, under the lead of the Mario Negri Institute for Pharmacological Research. Representatives from all consortium members participated in the workshop, as well as representatives of the EMA, EUnetHTA and the CTFG, who are associated partners of the PERMIT project.
PERMIT has launched a brief survey to to map patient stratification strategies currently undertaken by industry. It will contribute to a better understanding of the challenges and opportunities in the translational development phase of personalised medicine clinical trials
An abstract about PERMIT's scoping review was selected by the Cochrane Colloquium.
